angiotensin ii has been researched along with Scleroderma, Systemic in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Bergler-Czop, B; Brzezińska-Wcisło, L; Kopeć-Mędrek, M; Kotyla, P; Kucharz, E; Miziołek, B; Sieńczyk, M; Widuchowska, M | 1 |
| Leask, A; Lipson, KE; Makino, K; Makino, T; Stawski, L; Trojanowska, M | 1 |
| Hirano, K; Igarashi, J; Karita, S; Kubota, Y; Nakai, K; Tsukamoto, I | 1 |
| Asano, Y; Sato, S | 1 |
| Dietz, H | 1 |
| Sheppard, D; Tsujino, K | 1 |
| Chappell, MC | 1 |
| Fukasawa, C; Hara, M; Harigai, M; Kamatani, N; Kawaguchi, Y; Nishimagi, E; Sugiura, T; Takagi, K | 1 |
| Bartoli, F; Brosnihan, KB; Cerinic, MM; Cinelli, M; Ferrario, CM; Fiori, G; Generini, S; Guiducci, S; Livi, R; Perfetto, F; Pignone, A; Rogai, V; Rosso, AD; Tempestini, A | 1 |
| Avery, GS; Brogden, RN; Heel, RC; Speight, TM | 1 |
| Goldsmith, DJ | 1 |
| Abramenko, TV; Alekperov, RT; Balabanova, RM; Garats, EV; Kiselev, IP; Kost, OA; Miagkova, MA; Nikol'skaia, II; Stanislav, ML | 1 |
| Jia, L | 1 |
4 review(s) available for angiotensin ii and Scleroderma, Systemic
| Article | Year |
|---|---|
Animal models of scleroderma: current state and recent development.
Topics: Angiotensin II; Animals; Disease Models, Animal; DNA Topoisomerases, Type I; Fos-Related Antigen-2; Genetic Predisposition to Disease; Mice; Mice, Transgenic; Mutation; Proto-Oncogene Protein c-fli-1; Reactive Oxygen Species; Scleroderma, Systemic | 2013 |
Critical Appraisal of the Utility and Limitations of Animal Models of Scleroderma.
Topics: Angiotensin II; Animals; Bleomycin; Disease Models, Animal; Genetic Predisposition to Disease; Graft vs Host Disease; Mice; Mice, Transgenic; Reactive Oxygen Species; Scleroderma, Systemic | 2016 |
Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.
Topics: Aldosterone; Angiotensin II; Captopril; Drug Interactions; Heart Failure; Hemodynamics; Humans; Hypertension; Kallikreins; Kinetics; Kinins; Proline; Prostaglandins; Renin; Scleroderma, Systemic | 1980 |
[Some advances in angiotensin converting enzyme inhibitors].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Heart Failure; Humans; Hypertension; Oligopeptides; Prostaglandins; Scleroderma, Systemic; Structure-Activity Relationship; Teprotide | 1985 |
9 other study(ies) available for angiotensin ii and Scleroderma, Systemic
| Article | Year |
|---|---|
Significance of the angiotensin I/angiotensin II/angiotensin-(1-7) axis in the pathogenesis of systemic sclerosis.
Topics: Adult; Aged; Angiotensin I; Angiotensin II; Female; Humans; Male; Middle Aged; Peptide Fragments; Scleroderma, Systemic; Young Adult | 2020 |
Anti-connective tissue growth factor (CTGF/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis.
Topics: Actins; Angiotensin II; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cells, Cultured; Connective Tissue Growth Factor; Disease Models, Animal; Fibroblasts; Fibrosis; Humans; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Scleroderma, Systemic; Skin | 2017 |
COA-Cl prevented TGF-β1-induced CTGF expression by Akt dephosphorylation in normal human dermal fibroblasts, and it attenuated skin fibrosis in mice models of systemic sclerosis.
Topics: Adenosine; Angiotensin II; Animals; Cell Line; Connective Tissue Growth Factor; Disease Models, Animal; Drug Evaluation, Preclinical; Fibroblasts; Fibrosis; Humans; Male; Mice; Phosphorylation; Proto-Oncogene Proteins c-akt; Scleroderma, Systemic; Skin; Transforming Growth Factor beta1 | 2019 |
A healthy tension in translational research.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Awards and Prizes; Fibrillins; Humans; Loeys-Dietz Syndrome; Marfan Syndrome; Mice; Microfilament Proteins; Scleroderma, Systemic; Signal Transduction; Societies, Medical; Transforming Growth Factor beta; Translational Research, Biomedical; United States | 2014 |
Angiotensin-converting enzyme 2 autoantibodies: further evidence for a role of the renin-angiotensin system in inflammation.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Autoantibodies; Humans; Hypertension; Peptide Fragments; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Scleroderma, Systemic | 2010 |
Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors.
Topics: Adult; Aged; Angiotensin II; Angiotensinogen; Autocrine Communication; Blotting, Western; Cathepsin D; Cells, Cultured; Extracellular Matrix; Female; Fibroblasts; Fibrosis; Gene Expression; Humans; Immunohistochemistry; Male; Middle Aged; Procollagen; Receptor, Angiotensin, Type 1; RNA, Messenger; Scleroderma, Systemic; Skin; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2004 |
Reduced circulating levels of angiotensin-(1--7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control.
Topics: Angiotensin I; Angiotensin II; Antihypertensive Agents; Epoprostenol; Female; Humans; Male; Middle Aged; Neprilysin; Nitric Oxide; Peptide Fragments; Peptidyl-Dipeptidase A; Scleroderma, Systemic; Vasoconstrictor Agents | 2007 |
Angiotensin receptor antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Losartan; Scleroderma, Systemic; Tetrazoles | 1997 |
[Autoantibodies to vasoactive peptides and angiotensin converting enzyme in patients with systemic diseases of the connective tissue].
Topics: Angiotensin II; Arthritis, Rheumatoid; Autoantibodies; Blood Donors; Bradykinin; Humans; Immunoenzyme Techniques; Immunoglobulin M; Lupus Erythematosus, Systemic; Peptidyl-Dipeptidase A; Scleroderma, Systemic; Spectrometry, Fluorescence; Vasopressins | 2001 |